Compare Five Below Inc (FIVE) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Heron Therapeutics Inc — how do they compare? Five Below Inc trades at $209.72 (market cap $11.25B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Five Below Inc is far larger — about 151.9× Heron Therapeutics Inc's market cap, and Five Below Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and Heron Therapeutics Inc for 35 Days on average.
| FIVE | HRTX | |
|---|---|---|
Market Cap | $11.25B | $74.04M |
Volume | 986,546 | 3,668,095 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $1.49 |
52-Week Low | $138.49 | $0.27 |
Typical Hold Time | 46 Days | 35 Days |
Enterprise Value | $12.10B | $180.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $204.24, down 2.71% today but maintains strong analyst support with 60% buy ratings and a $298.44 consensus price target. The company shows robust revenue growth from $3.88B in 2025 to projected $5.3B in 2026, with earnings beating expectations in three consecutive quarters. Technical indicators show bearish momentum despite oversold RSI readings, with key support at $197.
FIVE presents a compelling growth story with expanding margins and strategic initiatives, though premium valuation (P/E 18.32) and execution risks warrant caution. The stock offers significant upside to analyst targets but faces near-term technical pressure and macroeconomic headwinds affecting consumer spending.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
